Novel lipid altering therapies will steer acute coronary syndrome market beyond $12 billion by 2022

12-Aug-2016 - The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound annual growth rate of 4.6%. The launch of several new lipid targeting therapies which offer clinical effectiveness for statin intolerant patients and ...

Venous Thromboembolism Therapeutics Market Set to Hit $3.7 Billion by 2025

04-Aug-2016 - The therapeutics market for venous thromboembolism (VTE), a condition which comprises deep vein thrombosis and pulmonary embolism, is set to rise from $2.8 billion in 2015 to $3.7 billion by 2025, representing a Compound Annual Growth Rate (CAGR) of 2.89%, according to research and consulting ...

Top Mid-Cap Biotech Companies Increased Revenues to $26.5 Billion in 2014, says GlobalData

Combined total revenues for peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014

09-Apr-2015 - The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9%, according to research and consulting firm GlobalData.The company’s report "PharmaLeaders: ...

Stem Cell Therapies Gathering Momentum but Significant Challenges Remain, says GlobalData

11-Dec-2014 - With 104 programs in late-stage clinical development, the stem cell therapy space could reach the commercialization threshold by 2017, but a number of challenges remain, according to research and consulting firm GlobalData.The company’s report "PharmaSphere: Emerging Biotechnologies – Stem Cell ...

Pfizer contemplates $2 billion acquisition of Strides’ Agila Unit

22-Jan-2013 - As drug makers continue to jostle for market share and deal with declining revenues from their off-patent blockbuster drugs, M&A activity is showing no indication of slowing down in 2013. Pfizer is not leaving any stone unturned as the company continues its growth. Less than two months after ...

H1N1 pandemic fears to maintain lofty US flu vaccination levels

11-Jan-2013 - US demand for influenza vaccines will remain high in the coming decade, following a post-flu pandemic spike, predicts business intelligence provider GlobalData. According to the company’s latest epidemiology report, seasonal influenza vaccine demand will increase from the 142 million expected for ...

Biotech Strategy Evolves in Big Pharma’s Footsteps

26-Nov-2012 - Biotech companies are exploring alternative options to supplement their in-house research and development (R&D), abandoning the traditional blockbuster drug model to instead pursue deals and buy their way to success, says healthcare intelligence providers GlobalData in a new report, which ...

Analyst Insight: Rapid Detection of Pandemics: Identifying the Unknown

10-Oct-2012 - A Severe Acute Respiratory Syndrome (SARS)-like coronavirus is back in the headlines. A Qatari national, recently returned from a trip to Saudi Arabia, was struck down by a mystery respiratory illness. A lack of diagnostic capability led to the patient being transferred from Qatar to London for ...

Mexico is Potential Pharma Exporter

22-Aug-2012 - The Mexican healthcare industry needs to readjust for the changing demographics of its citizens, states a new report by healthcare experts GlobalData.The new report, Healthcare, Regulatory and Reimbursement Landscape - Mexico, states that with a population of approximately 112 million, Mexico ...

The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis

10-Aug-2012 - The end of July 2012 proved exciting for the world of biosimilar manufacturers, according to GlobalData. However, for the regulatory officials worldwide it meant more uncertainty and unknowns about proper, global biosimilar guidelines. On July 23, 2012, South Korean biosimilar manufacturer ...